Icon watched its revenue swell by 20% last year, and now the Irish CRO is expecting a healthy rate of new business wins to fuel growth in 2014.
Icon, like most of the world's largest CROs, is investing in high-tech adaptive trial monitoring, and the company's latest offering allows investigators to comb through huge dumps of lab data in real time, tracking trial trends as they happen.
CRO giant Icon is riding high on another spike in revenue, again upping its full-year expectations after increasing profits by more than 50%.
Irish CRO Icon is riding the spike in demand for adaptive trial monitoring, unveiling a new service that parses study data and highlights potential safety issues in real time.
The FDA is encouraging drugmakers to embrace new methods of monitoring for clinical trials, and Icon is betting its latest offering can streamline how sponsors deal with study sites and save money in the process.
CRO Icon has signed a deal with the National Taiwan University Hospital, lending its weight in clinical research to help make local trials faster and more reliable.
Dublin's Icon nailed down another strong sales quarter, growing revenue 21% and increasing its full-year expectations.
While academic partnerships are nothing new in the CRO world, lately companies have been pairing up with schools to create degree programs designed to identify the next crop of clinical research talent, and now Icon and ClinTec have added their names to that list.
Icon posted $317 million in revenue last quarter, a 26% jump over the previous year, and the CRO more than doubled its net income.
Irish CRO Icon pulled down a monster fourth quarter, with revenue skyrocketing 24% to $300 million, and the company predicts an even brighter 2013, projecting annual revenue of up to $1.3 billion, good for a 12% jump.